anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Weekly isotretinoin (at 1-1.5 mg/kg per week) dose preceded by a 5-day daily loading dose (0.5-1 mg/kg/day). The weekly dose will be given once a week for 4 months.
The invention discloses an oral disintegrating tablet containing escitalopram oxalate. The preparation is composed of a filling agent, especially referring to mannitol with good taste, microcrystalline cellulose having a certain disintegration function, an adhesive, a disintegrating agent, a flavoring agent and a lubricating agent. Silicon dioxide is added, so that the taste is effectively improved. When a patient takes the escitalopram oxalate oral disintegrating tablet disclosed by the invention, no water or less water is required and no chewing is required; when the drug is placed into the oral cavity, the drug is quickly dissolved or disintegrated after meeting saliva, and then the drug enters the digestive system following the autonomous or heteronomous swallowing action of the patient and then is absorbed and becomes effective. The oral disintegrating tablet is suitable for the acute and maintenance treatment for major depressive disorder of an adult and the acute treatment for generalized anxiety disorder of the adult. The invention also provides a preparation method which is simple in technique, is low in cost and belongs to the field of pharmaceutical technology.
Carrot juice under liquid form. Oral administration. Dosage 100 ml. To drink 1h00 before alcohol intake together with meal.
<P>PROBLEM TO BE SOLVED: To provide a porous polymer particle having excellent touch feeling and high oil absorption; to provide a method for producing the porous polymer particle, a gel-shaped composition and a cosmetic containing the particle.  <P>SOLUTION: The porous polymer particle is obtained by allowing (A) 60-100 mass% monomer in the whole monomers to have <8.8 solubility parameter, and (B) 0.02-15 pts. by mass of a crosslinking agent based on 100 pts. by mass of the whole monomers to be present in a W/O/W type emulsion, and polymerizing the monomers. The method for producing the porous polymer particle, the gel-shaped composition containing an oily component and the porous polymer particle, and the cosmetic containing the porous polymer particle are also provided.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
The present invention relates to promoters, enhancers and other regulatory elements that direct expression within tumor and tissue cells with calcification potential. In particular, it relates to compositions comprising nucleotide sequences from the 5′ regulatory region, and transcriptionally active fragments thereof, that control expression of a bone sialoprotein (“BSP”). Specifically provided are expression vectors, host cells and transgenic animals wherein a BSP regulatory region is capable of controlling expression of a heterologous coding sequence, over-expressing an endogenous BSP coding sequence or an inhibitor of a pathological process or knocking out expression of a specific gene believed to be important for a calcification-related disease in tumor and tissue cells with calcification potential. The invention also relates to methods for using said vectors, cells and animals for screening candidate molecules for agonists and antagonists of disorders involving tumor and tissue cells with calcification potential. The present invention further relates to compositions and methods for modulating expression of compounds within tumor and tissue cells with calcification potential. Methods for using molecules and compounds identified by screening assays for therapeutic treatments also are provided. The invention further relates to methods of treating tumors and other diseases and disorders involving tumor and tissue cells with calcification potential.
Fatigue is the most common symptom of multiple sclerosis (MS), affecting up to 90% of people with the disease. MS-related fatigue can be disabling even when other features of MS are mild. It can interfere with physical activity, memory and thinking, social and family activities, and ability to work. Initial treatment consists of energy conservation techniques such as rest periods or naps but when these approaches fail doctors usually recommend a trial of medications. Amantadine, modafinil, and other stimulants are commonly used but help only about half of those who try them. It is unlikely that these drugs directly affect the cause of MS-related fatigue.

It has been difficult to develop new drug therapies for MS-related fatigue because we do not fully understand its causes and do not have precise ways to measure it. We rely on a person's self-report about their fatigue but individuals experience and report fatigue differently. Recent research has shown that some fatigue aspects, such as difficulty maintaining mental concentration ("cognitive fatigue") and physical activity ("motor fatigue"), can be measured more precisely and require further study.

We recently reported results from a study showing that people taking the equivalent of four regular aspirin tablets (1300 mg) daily had reduced MS-related fatigue compared with placebo (sugar pill). The current proposal will attempt to confirm the benefit of aspirin in a larger group of people and to determine if the benefit is related to inflammation. One hundred and thirty-five people with MS-related fatigue will participate at MS clinics at three Mayo Clinic sites. Participants will complete questionnaires that ask about the severity and impact of their fatigue, memory testing to assess cognitive fatigue, and have blood testing to measure markers of inflammation. At the Arizona site, participants will also do strength testing in a motor laboratory to assess motor fatigue. After obtaining two separate baseline evaluations, the participants will be randomly assigned treatment such that one-third will receive 1300 mg per day of aspirin, one-third will receive 162 mg per day of aspirin and one-third will receive a matching placebo. All participants will then return to the clinic on two more occasions over the next eight weeks to repeat the questionnaires, memory and strength testing, blood tests, and report any side-effects. At the end of the study, the results of one of the fatigue questionnaires will be analyzed to determine if aspirin significantly improved fatigue compared with the placebo. The results of other questionnaires and the memory and strength testing will be analyzed as supportive evidence.

If this study is successful, it will provide strong scientific evidence that aspirin helps MS-related fatigue. It will add an important new option for treatment of all MS patients that is also familiar, inexpensive, and has a good long-term safety record. At the same time, it will allow us to better understand the causes of MS-related fatigue and how to measure it more precisely. This information will be extremely useful for development of other therapies in the future.
Hospitalized patients with T2D admitted in non-critical medical and surgical wards. The participants use FreeStyle 2-CGM with deactivated alarms. Blind will be applied for patients, nurses and physicians in charge of the investigation. Concomitant 6-point CG controls will be performed (before each meal and two hours after meals) with Abbott FreeStyle Optium Neo glucometer. Insulin therapy adjustments will be carried out by GC only. The CGM values in this group will be evaluated a posteriori. Basal-bolus schedule with basal insulin Glargine U-100 and prandial insulin Aspart will be used. Daily adjustments will be made based on protocols of our department according to the international guidelines.
Objective:To evaluate the outcomes following the use of folded supraclavicular flap repaired hypopharyngeal combined neck skin defects. Methods:Folded supraclavicular flap were designed to repaired four cases of hypopharyngeal combined neck skin defects patients. Evaluate their repair effect (3 men,1 woman; mean age:66 years). Hypopharyngeal fistula from 3.2 cm×1.8 cm to 4.5 cm×3.8 cm,skin defects in the neck from 3.8 cm×2.2 cm to 5.1 cm×4.5 cm. The folded supraclavicular flap from 8 cm×5 cm to 13 cm×9 cm. Results:All flaps survived, head and neck appearance was satisfactory, and no patient experienced a major complication. All patients resumed an oral diet function. No fistula recurrence or stricture developed after 6-19 months of follow-up. Conclusion:The folded supraclavicular flap is a safe and effective flap Repaired for hypopharyngeal combined neck skin defects.
A method, comprising: the first request and the first session token are sent by the site (104) to the cloud based CDSS (102). The first request is for an action to be performed by the CDSS on the de-identified data stored at the CDSS. The method further comprises the following steps: a second request and a second session token sent by the CDSS to the site are received at the site. The second request requests authentication of a second session token. The method further comprises the following steps: at the site, comparing the first session token with the second session token. The method further comprises the following steps: verifying, at the site, the second session token in response to the first session token and the second session token being the same token, and generating a verification signal. The method further comprises the following steps: sending, by the site, the verification signal to the CDSS. The method further comprises the following steps: at the site, receiving an indication that the CDSS performed the requested action.
FIELD: genetic engineering, medicine, proteins, pharmacy. SUBSTANCE: invention relates to a novel polypeptide that inhibits binding TGF-alpha (growth factor of T-cells) with its receptors. Amino acid sequence of said polypeptide is given in description. Urine is adsorbed on kaolin at acid pH value, extracted with ammonia, obtained fractions are eluted on resin Bio Rex 70 using ammonia. Obtained after elution fractions are eluted on DEAE-Sepharose resin using acetate buffer, then on CM-Sepharose using acetate buffer, then on resin HPLC C-18 using a mixture of acetate buffer with acetonitrile, then elution is carried out on resin DE-52 using acetate buffer, then on resin D-Zephyr using acetate buffer, then on resin HPLC C-18 using a mixture of an aqueous trichloroacetic acid and acetonitrile and then on resin D-Zephyr using acetate buffer that results to preparing polypeptide or polypeptide-containing pure protein. Polypeptide is encoded by DNA nucleotide sequence given in the claim of invention. Expressing vector involves DNA fragment encoding polypeptide. Strain E.coli is transformed with expressing vector and produces polypeptide with amino acid sequence given in description. Polypeptide is produced also by culturing procaryotic or eucaryotic cells transformed with expressing vector and by its isolation from cultural medium. Pharmaceutical composition that is able to inhibit binding TGF-alpha has therapeutically acceptable amount of polypeptide or pure protein in combination with one or some therapeutically acceptable filling agents or vehicles. Medicinal agent eliciting anti-inflammatory and/or anticoagulating and/or antitumor activity has polypeptide with amino acid sequence given in the claim. Invention ensures to produce a novel protein with relatively low molecular mass that can be used in preparing anti-inflammatory, anticoagulating agents for treatment and agents eliciting antitumor activity also. EFFECT: improved method of producing, valuable medicinal properties of polypeptide. 20 cl, 8 dwg, 4 ex
PCT No. PCT/JP95/02109 Sec. 371 Date Apr. 14, 1997 Sec. 102(e) Date Apr. 14, 1997 PCT Filed Oct. 13, 1995 PCT Pub. No. WO96/11584 PCT Pub. Date Apr. 25, 1996A method for producing a peptide mixture from whey protein by (1) adding at least one protease to an aqueous solution of at least one whey protein to hydrolyze the whey protein, (2) measuring the amount of a free amino acid selected from the group consisting of lysine, phenylalanine, leucine and arginine produced during the hydrolysis of the whey protein, (3) calculating the amount of the free amino acid with respect to the total amount of the amino acid contained in the whey protein, and (4) terminating the hydrolysis when the calculated amount of the free amino acid with respect to the total amount of the amino acid contained in the whey protein falls within a predetermined range. The inventive method provides a whey protein hydrolysate of consistent quality.
Using RT-PCR and degenerate oligonucleotides derived from the active site residues of subtilisin-kexin-like serine proteinases, we have identified a highly conserved and phylogenetically ancestral human, rat and mouse type-I  membrane-bound proteinase called subtilisin-kexin-isozyme-1 (SKI-1). Computer data bank searches reveals that human SKI-1 was previously cloned but with no identified function. In situ hybridization demonstrates that SKI-1 mRNA is widely distributed, e.g., in thymus, in adrenal, submaxillary and pituitary glands, in skin, teeth, ribs, intestines, cortex of the kidney and brain, cerebellum, retina, and hippocampus. Cleavage specificity studies show that SKI-1 generates a 28 kDa product from the 32 kDa brain-derived neurotrophic factor precursor (proBDNF) cleaving at an RGLT~SL  bond. In HK293 cells, proSKI-1 processed in two steps at the level of the endoplasmic reticulum and a large fraction of the membrane-bound enzyme is released into the medium. Immunocytochemical analysis shows that SKI-1 is present in the Golgi apparatus and within small punctate structures reminiscent of endosomes. In vitro studies suggest that SKI-1 is a Ca2+-dependent serine proteinase exhibiting a wide pH optimum for cleavage of proBDNF.
Cisplatin-based combination chemotherapy produces a response rate of 40-70% in TCC patients. However, only less than 10% of the patients can achieve long-term remission. Until now, there is no standard chemotherapy for cisplatin-failed TCC patients. Both gemcitabine and ifosfamide have been identified to have response rates of 20% or more in pretreated TCC patients. It is thus reasonable to combine these two active drugs as a second-line treatment for TCC.

Patients enrolled must have a pathologically proven urothelial transitional cell carcinoma (TCC) and must have exposed to one cisplatin-based combination chemotherapy for the advanced disease. GI regimen will be continued until maximal response.
In the control group, participants will attend the standard 15-week Transform program, with education sessions delivered through traditional lectures by health educators from ICM on the topics of income creation, education, food security, and resilience. Our educational toolkit of MMR and polio vaccination will not be provided and there will be no specific reminders or discussions regarding MMR and polio vaccinations.
BACKGROUND: High blood pressure has been suggested to accelerate vascular injury-induced neointimal formation and progression. However, little is known about the intricate relationships between vascular injury and hypertension in the context of arterial remodeling.
METHODS: Single-cell RNA-sequencing analysis was used to depict the cell atlas of carotid arteries of Wistar Kyoto rats and spontaneously hypertensive rats with or without balloon injury.
RESULTS: We found that hypertension significantly aggravated balloon injury-induced arterial stenosis. A total of 36 202 cells from carotid arteries with or without balloon injury were included in single-cell RNA-sequencing analysis. Cell composition analysis showed that vascular injury and hypertension independently induced distinct aortic cell phenotypic alterations including immune cells, endothelial cells (ECs), and smooth muscle cells. Specifically, our data showed that injury and hypertension-induced specific EC phenotypic alterations, and revealed a transition from functional ECs to hypermetabolic, and eventually dysfunctional ECs in hypertensive rats upon balloon injury. Importantly, our data also showed that vascular injury and hypertension-induced different smooth muscle cell phenotypic alterations, characterized by deferential expression of synthetic signatures. Interestingly, pathway analysis showed that dysregulated metabolic pathways were a common feature in monocytes/macrophages, ECs, and smooth muscle cells in response to injury and hypertension. Functionally, we demonstrate that inhibition of mitochondrial respiration significantly ameliorated injury-induced neointimal formation in spontaneously hypertensive rats.
CONCLUSIONS: This study provides the cell landscape changes of the main aortic cell phenotypic alterations in response to injury and hypertension. Our findings suggest that targeting cellular mitochondrial respiration could be a novel therapeutic for patients with hypertension undergoing vascular angioplasty.
The invention relates to a bad breath navel patch and a preparation method thereof. The agent layer comprises the following components: 3-5 parts of mint, 1-3 parts of borneol, 1-3 parts of rosemary, 1-3 parts of clove, 1-5 parts of bergamot extract oil, 1-3 parts of lily, 10-20 parts of water-absorbent resin and 3-5 parts of ethylenediaminetetraacetic acid disodium salt. The preparation method comprises the following steps: mixing the components, adding 50-60 parts of pure water, stirring to be uniform, coating the mixture onto a lining cloth layer, and preparing the plaster patch. The bad breath navel patch disclosed by the invention is made of pure traditional Chinese medicines and is reasonable in compatibility of medicines, and the drug effects complement each other; and the patch is simple in method and safe to use and does not have any side effect. During use, the patch is attached to the navel, does not have any side effect and is fast in curative effect. According to the treatment mode of treating an internal illness by external treatment, the aim of treating persistent bad breath can be achieved, and the bad breath navel patch is easily accepted by patients.
BACKGROUND: Trypanosoma cruzi and HIV coinfection can evolve with depression of cellular immunity and increased parasitemia. We applied quantitative PCR (qPCR) as a marker for preemptive antiparasitic treatment to avoid fatal Chagas disease reactivation and analyzed the outcome of treated cases.
METHODOLOGY: This mixed cross-sectional and longitudinal study included 171 Chagas disease patients, 60 coinfected with HIV. Of these 60 patients, ten showed Chagas disease reactivation, confirmed by parasites identified in the blood, cerebrospinal fluid, or tissues, 12 exhibited high parasitemia without reactivation, and 38 had low parasitemia and no reactivation.
RESULTS: We showed, for the first time, the success of the timely introduction of benznidazole in the non-reactivated group with high levels of parasitemia detected by qPCR and the absence of parasites in reactivated cases with at least 58 days of benznidazole. All HIV+ patients with or without reactivation had a 4.0-5.1 higher chance of having parasitemia than HIV seronegative cases. A positive correlation was found between parasites and viral loads. Remarkably, treated T. cruzi/HIV-coinfected patients had 77.3% conversion from positive to negative parasitemia compared to 19.1% of untreated patients. Additionally, untreated patients showed ~13.6 times higher Odds Ratio of having positive parasitemia in the follow-up period compared with treated patients. Treated and untreated patients showed no differences regarding the evolution of Chagas disease. The main factors associated with all-cause mortality were higher parasitemia, lower CD4 counts/μL, higher viral load, and absence of antiretroviral therapy.
CONCLUSION: We recommend qPCR prospective monitoring of T. cruzi parasitemia in HIV+ coinfected patients and point out the value of pre-emptive therapy for those with high parasitemia. In parallel, early antiretroviral therapy introduction is advisable, aiming at viral load control, immune response restoration, and increasing survival. We also suggest an early antiparasitic treatment for all coinfected patients, followed by effectiveness analysis alongside antiretroviral therapy.
Thirty children were between two and five years of age at the time of implantation. All were congenital pre-linguistically bilateral profound sensorineural hearing loss. Reports about basic audiological evaluation which included air and bone conduction thresholds, speech audiometry for all the study group before the implantation were obtained. They had limited benefit from consistent use of hearing aid amplification and enrolled in a rehabilitation program focused on oral communication. they underwent unilateral CI with CI experience ranged from 6 months and above.
Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biologically, or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant. A release-rate controlling component is incorporated into the matrix to control the rate of release of the encapsulant from the particles. The additional component may be a hydrophobic component or a high water binding capacity component for extending the release time. The plasticizable matrix material, such as starch, is admixed with at least one plasticizer, such as water, and at least one release-rate controlling component under low shear mixing conditions to plasticize the plasticizable material without substantially destroying the at least one plasticizable material and to obtain a substantially homogeneous plasticized mass. The plasticizer content is substantially reduced and the temperature of the plasticized mass is substantially reduced prior to admixing the plasticized mass with the encapsulant to avoid substantial destruction of the encapsulant and to obtain a formable, extrudable mixture. The mixture is extruded though a die without substantial or essentially no expansion and cut into discrete, relatively dense particles. Release properties may also be controlled by precoating the encapsulant and/or coating the extruded particles with a film-forming component.
The invention discloses a traditional Chinese oral preparation for treating hepatitis B. The traditional Chinese oral preparation is prepared from the following active ingredients in parts by weight: 20-30 parts of poria cocos, 20-30 parts of kelp, 20-30 parts of leonurus, 10-20 parts of lalang grass rhizome, 10-20 parts of scutellaria baicalensis, 10-20 parts of gentiana rigescens, 5-15 parts of folium mori, 5-15 parts of trogopterus dung and 5-10 parts of liquorice. The traditional Chinese medicine preparation has the effects of clearing away heat and toxic materials, smoothening liver to release dampness and the like, and is applicable to viral hepatitis B. When being used, the preparation is orally taken twice a day, and 10g of the preparation is taken each time. The traditional Chinese medicine preparation has remarkable curative effects on hepatitis B, and the positive HBsAg HBeAg HBcAb can be turned into virus carry after the preparation is taken for 1 to two mouths. Clinical tests show that the effective rate is 94.8%, and the preparation has the advantages of rapidness in taking effect, definiteness in curative effect, high efficiency, good long-term effect and the like.
Conduct 15 interviews with patients diagnosed with FH. Interviews will be 30-60 minutes in length and will focus on how individuals understand cascade screening, barriers to engagement including reasons why individuals do and do not share health information with family members, and preferred approaches to engaging family members, with a focus on acceptability, appropriateness, and feasibility of the planned implementation strategies. Interviewers will also attend to structural factors such as medical mistrust and experiences of racism in health care, and ask about preferences and logistics to incorporate preference into the future clinical trial design.